Loading...
Market
How will Finch Therapeutics' stock price performance compare to the biotech sector by June 30, 2025?
3
Resolution / Starting Odds
Significantly outperform • 25%
Slightly outperform • 25%
Match sector performance • 25%
Underperform • 25%
Public stock market data and sector performance indices
Story
Finch Therapeutics Wins $26 Million Legal Judgment, Stock Soars 350%
Aug 11, 2024, 01:45 AM
Finch Therapeutics (FNCH), a microcap company, has been awarded a legal judgment totaling $26 million, including $25 million in damages and approximately $800,000 in royalties from ITD Rebyota sales. This outcome is significant for the company, which had a market cap of $6 million and cash reserves of around $15 million. The legal victory is expected to boost the company's cash position to over $40 million. The stock, which was valued at less than $1 with a market cap of $1.5 million as of June 2, has seen a substantial increase, rising by approximately 350% since the announcement of the legal judgment. This development marks a notable turnaround for Finch Therapeutics, potentially altering market perceptions of its financial stability.
View original story
Similar markets
Less than 50% • 25%
50% to 100% • 25%
100% to 200% • 25%
More than 200% • 25%
Yes • 50%
No • 50%
Outperforms NASDAQ • 25%
Performs on par with NASDAQ • 25%
Underperforms NASDAQ • 25%
Delisted from NASDAQ • 25%
Outperforms competitors • 25%
Matches competitors • 25%
Underperforms competitors • 25%
Significantly underperforms competitors • 25%
Higher than competitors • 25%
On par with competitors • 25%
Lower than competitors • 25%
Significantly lower than competitors • 25%
Outperforms biotech index • 33%
Matches biotech index • 33%
Underperforms biotech index • 33%
Stock increases by 10% or more • 25%
Stock remains within +/- 10% • 25%
Stock decreases by 10% or more • 25%
Stock remains volatile with no clear trend • 25%
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly Underperform • 25%
